Sakar Healthcare has notified the National Stock Exchange of India Ltd of an upcoming Board of Directors meeting, scheduled in accordance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted on 6th May, 2026, by Bharat Soni, Company Secretary and Compliance Officer of the company.

Board Meeting Details

The key details of the scheduled board meeting are outlined below:

Purpose of the Meeting

The Board of Directors will convene to consider, approve, and take on record the Audited Financial Results — covering both Standalone and Consolidated statements — for the Financial Year 2025-26 ended on 31st March, 2026. The meeting will also address other matters as deemed appropriate by the board.

Trading Window Closure

In compliance with the company's Code of Conduct for prevention of Insider Trading and SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for designated persons will continue to remain closed. As previously communicated to the Exchange vide letter dated 24th March, 2026, the Trading Window closure will remain in effect until 48 hours after the declaration of the Audited Financial Results for the year ended 31st March, 2026.

The intimation was digitally signed and submitted by Bharat Soni, Company Secretary and Compliance Officer of Sakar Healthcare, on 6th May, 2026.

Sakar Healthcare Limited has been honored with a prestigious recognition award from the Ethiopian Pharmaceutical Supply Services (EPSS) for its outstanding performance during the 2024-25 period. The company received a crystal trophy acknowledging its excellence in fulfilling contractual commitments as one of the best suppliers.

Award Recognition Details

The Ethiopian Pharmaceutical Supply Services formally recognized Sakar Healthcare's exceptional service delivery and commitment to contractual obligations. The award ceremony highlighted the company's consistent performance standards and reliability in the Ethiopian pharmaceutical supply chain.

Partnership Acknowledgment

The Director General at EPSS expressed appreciation for Sakar Healthcare's valued partnership and emphasized the importance of maintaining this momentum for future business opportunities. The recognition specifically highlighted the company's remarkable performance and excellence in meeting contractual commitments throughout the award period.

The EPSS leadership indicated positive expectations for continued collaboration, including new business ventures and refill orders to Ethiopia. This recognition strengthens Sakar Healthcare's position in the Ethiopian pharmaceutical market and demonstrates its capability to meet international supply standards.

Regulatory Disclosure

Sakar Healthcare disclosed this achievement under Regulation 30 of the LODR (Listing Obligations and Disclosure Requirements) regulations. The company communicated this development to the National Stock Exchange of India, ensuring transparency with stakeholders and investors about this significant business milestone.

The formal disclosure was signed by Bharat Soni, Company Secretary and Compliance Officer, emphasizing the company's commitment to regulatory compliance and stakeholder communication. This recognition represents a notable achievement in Sakar Healthcare's international business operations and supplier relationships.